ATLAB Pharma and BZL Biologics Announce Exclusive Global Licensing Agreement for Lu-J591, a Novel Radiopharmaceutical in Phase IIB for the Treatment of Prostate Cancer

Published: Oct 28, 2011

NANTES, France--(BUSINESS WIRE)--ATLAB Pharma SAS and BZL Biologics LLC have entered into a sublicense agreement to develop 177Lu-J591 for cancer treatment. It includes exclusive rights to manufacture, develop and commercialize this radiopharmaceutical product worldwide as well as a joint Phase IIB/III clinical validation program.

Back to news